Adjuvant treatment with a capecitabine-containing chemotherapy regimen could improve the overall survival of patients with early breast cancer, suggest long-term follow-up data from the phase 3 FinXX trial.

The second-generation irreversible pan-HER tyrosine kinase inhibitor pyrotinib in combination with capecitabine shows promising activity against brain metastases in women with HER2-positive metastatic breast cancer, say researchers.

Ingrid Mayer discusses findings from the ECOG-ACRIN EA1131 trial showing no benefit of postoperative platinum-based chemotherapy versus capecitabine in patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy.

Maintenance therapy with low-dose capecitabine significantly reduces the risk for relapse or death in women with early-stage triple-negative breast cancer, show data from the phase 3 SYSUCC-001 trial.

Palbociclib plus endocrine therapy does not improve progression-free survival compared with capecitabine in women with aromatase inhibitor-resistant metastatic breast cancer, results of the phase 3 PEARL study show.

The addition of the orally administered taxane tesetaxel to reduced-dose capecitabine achieves a significant progression-free survival benefit in individuals with hormone receptor-positive, metastatic breast cancer who have previously received a taxane, suggest phase 3 trial findings.

The addition of capecitabine to trastuzumab emtansine does not improve the clinical outcomes of patients with previously treated HER2-positive metastatic breast cancer, indicates the phase 1/2 TRAXHER2 study.

Women with triple-negative breast cancer have significantly better outcomes with capecitabine-containing adjuvant chemotherapy than a standard regimen, suggests a phase 3 Chinese trial.

Patients with residual invasive disease after standard neoadjuvant chemotherapy for HER2-negative breast cancer benefit from adjuvant treatment with capecitabine, CREATE-X trial data show.

Adding capecitabine to gemcitabine in the adjuvant setting significantly improves overall survival in patients with resected pancreatic ductal adenocarcinoma, the ESPAC-4 trial shows.

“Overall, patients who received trastuzumab deruxtecan remained on treatment longer, had higher objective response rates [ORRs], and longer duration of response, progression-free survival [PFS], and overall survival [OS]” than those given capecitabine plus either trastuzumab or lapatinib, write the researchers in The Lancet .

This was nearly double the median PFS achieved by their counterparts who received investigator’s choice of docetaxel plus capecitabine, paclitaxel plus gemcitabine, or capecitabine plus vinorelbine, at 12.3 months, and equated to a significant 46% reduction in the risk for progression or death with ribociclib plus ET.

ESMO 2022 video The current presentation focused on the second interim analysis for OS, which was conducted at a median follow-up of 12.5 months and demonstrated that OS was significantly prolonged for the 272 participants who were randomly allocated to receive sacituzumab govitecan 10 mg/kg on days 1 and 8 of every 21-day cycle compared with the 271 patients who instead received physician’s choice of capecitabine, vinorelbine, gemcitabine, or eribulin.

The primary endpoint was independently assessed progression-free survival (PFS) in the hormone receptor-positive population, and this was significantly longer for the 331 participants who were randomly assigned to receive T-DXd 5.4 mg/kg every 3 weeks than for their 163 counterparts who instead received physician’s choice of capecitabine, eribulin, gemcitabine, paclitaxel, or nab-paclitaxel.

This was significantly longer than the median duration of 4.0 months for their 271 counterparts who instead received physician’s choice of capecitabine, vinorelbine, gemcitabine, or eribulin.

The addition of tucatinib to trastuzumab plus capecitabine continues to confer an overall survival benefit in advanced HER2-positive breast cancer over longer follow-up, show phase 2 data.

The phase 3 trial investigators randomly assigned 622 patients from 31 countries who had received one or two prior treatments for metastatic TNBC to receive pembrolizumab 200 mg every 3 weeks for 35 cycles or an investigator’s choice of single-agent chemotherapy, either capecitabine, eribulin, gemcitabine, or vinorelbine.

The 536 trial participants – all of whom had received at least two prior HER2-directed therapies and 1–3 nonhormonal treatments for metastatic disease – were randomly assigned to receive either margetuximab 15 mg/kg or trastuzumab 6 mg/kg (loading dose 8 mg/kg) once every 21 days alongside physician’s choice of capecitabine, eribulin, gemcitabine, or vinorelbine.

The CHMP has also granted a conditional marketing authorization for the HER2 kinase inhibitor tucatinib in combination with trastuzumab and capecitabine as a third- or later-line treatment for HER2-positive locally advanced or metastatic breast cancer patients.

Supplementing capecitabine with neratinib instead of lapatinib is associated with a significant improvement in the progression-free survival of previously treated patients with metastatic HER2-positive breast cancer, shows the phase 3 NALA trial.